BNTX - BioNTech SE

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.92
+0.17 (+1.33%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.75
Open12.99
Bid12.84 x 1400
Ask15.00 x 800
Day's Range12.53 - 12.99
52 Week Range12.52 - 16.70
Volume484,659
Avg. Volume1,689,733
Market Cap2.965B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • UPDATE 1-European biotech firm BioNTech reverses course in early trading
    Reuters

    UPDATE 1-European biotech firm BioNTech reverses course in early trading

    Shares of BioNTech SE tumbled nearly 12% in afternoon trade, erasing all its gains from earlier on Thursday, another sign of weakness in the IPO market after the collapse of WeWork's market debut. The shares backpedalled even though the German biotech firm downsized its initial public offering (IPO) and priced its stock below an earlier expected range on Wednesday. A bout of stock market volatility fueled by worries over the potential economic impact of a trade war between the United States and China has led to IPO hopefuls delaying their listings or shares of those recently listed floundering.

  • Reuters

    European biotech firm BioNtech jumps 10% in U.S. market debut

    Shares of BioNTech SE jumped on their market debut on Thursday, after the German biotech firm downsized its initial public offering (IPO) and priced its stock below an earlier expected range. The shares, whose launch was the latest test of fragile sentiment this year for primary stock market offerings, opened up 10% at $16.50 and rose as high as $16.69 in early trading on Nasdaq, giving the company a market valuation of $3.78 billion. The final pricing of its public flotation at $15 per ADS helped BioNtech raise about $150 million less than a month after the dramatic collapse of another major IPO for WeWork owner The We Company.

  • Benzinga

    The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) ...

  • Business Wire

    BioNTech Announces Pricing of Initial Public Offering

    BioNTech SE , a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, today announced the pricing of its initial public offering of 10,000,000 American Depositary Shares representing 10,000,000 ordinary shares at a public offering price of $15.00 per ADS, for gross proceeds of $150,000,000.

  • Benzinga

    IPO Outlook For The Week: Banking And Biotech

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. BioNTech SE (NASDAQ: BNTX ) will issue 13.2 million shares between ...